Literature DB >> 3120317

The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.

L Levin1, W Hryniuk.   

Abstract

An attempt was made using dose intensity to resolve some of the conflicting issues regarding chemotherapy in ovarian cancer and endometrial cancer. Analyses were done to determine if dose intensity correlates with outcome of first-line and salvage chemotherapy of advanced ovarian cancer and chemotherapy of advanced endometrial cancer. The concept of dose intensity was used to analyze the relative contributions of individual drugs, such as cyclophosphamide, hexamethylmelamine, Adriamycin (Adria Laboratories, Columbus, OH) and cisplatin to outcome, and to suggest how such drugs should be used in combination.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3120317

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  7 in total

Review 1.  Clinical pharmacokinetics-pharmacodynamics of anticancer drugs.

Authors:  W E Evans; M V Relling
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

2.  300 mg/m2 carboplatin (Cb), adriamycin (A) cyclophosphamide (C) (CACb-300) combination in advanced ovarian carcinoma: a feasibility study.

Authors:  P Martin; R Bugat; G Pinon; M C Pinel; F Heritier; M Chazard; M C Delestrain; D Belpomme
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Calculation of received dose intensity for combinations of drugs using small-cell lung carcinoma treatment regimens as examples.

Authors:  G L Wampler; J G Fryer
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Measures of renal function in patients with cisplatin-related chronic renal disease.

Authors:  E Reed; J Jacob; O Brawley
Journal:  J Natl Med Assoc       Date:  1991-06       Impact factor: 1.798

5.  5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity.

Authors:  F Franchi; C Barone; E Ricevuto; A Cassano; A Astone; C Pozzo; L Sofo; G Netri; C Ratto; C Coco
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

6.  Dose intensity analysis in advanced ovarian cancer patients.

Authors:  V Torri; E L Korn; R Simon
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

7.  A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.

Authors:  P Pronzato; G Bertelli; A Vigani; F Vaira
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.